XL019 – 10 mg

Brand:
Cayman
CAS:
945755-56-6
Storage:
-20
UN-No:
Non-Hazardous - /

Janus-associated kinases (JAKs) are cytoplasmic tyrosine kinases that are required for activating the signaling of certain cytokines and growth factor receptors. Many myeloproliferative diseases have been linked to a mutation in JAK2 where a switch from valine to phenylalanine occurs at the 617 position (V617F).{27171} Furthermore, constitutive activation of the JAK2 signaling pathway is associated with aggressive adult T cell leukemia/lymphoma.{27172} XL019 is a potent, bioavailable JAK inhibitor with preference for JAK2 (IC50 = 2 nM) over JAK1 and JAK3 (IC50s = 130 and 250 nM, respectively).{27725,21781} It is effective against JAK2V617F as well as JAK2 and inhibits phosphorylation of STAT5 in vivo.{27397}  

 

Out of stock

SKU: - Category:

Description

A potent, bioavailable JAK inhibitor with preference for JAK2 (IC50 = 2 nM) over JAK1 and JAK3 (IC50s = 130 and 250 nM, respectively); effective against JAK2V617F as well as JAK2 and inhibits phosphorylation of STAT5 in vivo


Formal name: (2S)-N-[4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide

Synonyms: 

Molecular weight: 444.5

CAS: 945755-56-6

Purity: ≥90%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|JAK Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|JAK Signaling||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors